NEWS CENTER |
|
2021
January 2, 2021
Photonic Pharma LLC is pleased to announce that its collaboration and license agreement continues with Bristol-Myers Squibb (NYSE:BMY).
Photonic Pharma LLC is pleased to announce that its collaboration and license agreement continues with Bristol-Myers Squibb (NYSE:BMY).
January 15, 2021
Photonic Pharma LLC is pleased to announce that it was awarded its second SBIR Phase I grant from the National Institute on Aging at the National Institutes of Health related to new therapeutic avenues for treatment of Alzheimer's disease. The project title is "Drug Discovery Pipeline Targeting Pathologically Leaky Calcium Release Channels in Age-Related Indications" (Project Number: R43AG069582). The awarded amount is $499,443. This project will be carried out by Photonic Pharma MPIs Razvan L. Cornea and Jennifer Jewell Thomas (contact PI), in collaboration with the University of Minnesota (Courtney C. Aldrich) and Rosalind Franklin University (Grace E. Stutzmann).
Photonic Pharma LLC is pleased to announce that it was awarded its second SBIR Phase I grant from the National Institute on Aging at the National Institutes of Health related to new therapeutic avenues for treatment of Alzheimer's disease. The project title is "Drug Discovery Pipeline Targeting Pathologically Leaky Calcium Release Channels in Age-Related Indications" (Project Number: R43AG069582). The awarded amount is $499,443. This project will be carried out by Photonic Pharma MPIs Razvan L. Cornea and Jennifer Jewell Thomas (contact PI), in collaboration with the University of Minnesota (Courtney C. Aldrich) and Rosalind Franklin University (Grace E. Stutzmann).
February 26, 2021
Photonic Pharma LLC is pleased to announce that it was awarded its its third grant from the National Institutes of Health, as a five-year Academic Industrial Partnership grant from the National Cancer Institute to the University of Minnesota, with a $234,000 annual subaward to Photonic Pharma, related to new therapeutic avenues for treatment of cancer through an innovative new approach to developing allosteric kinase inhibitors. The project title is "A transformative drug discovery platform for allosteric kinase inhibitors” (Project Number: R01 CA255513-01). This multi-PI collaboration is led by Principal Investigator, Nicholas M. Levinson (Contact) at the University of Minnesota and David D. Thomas, Principal Investigator at Photonic Pharma. Photonic Pharma holds an Exclusive Patent License Agreement with the University of Minnesota for a patent pending on protein kinase allostery sensor and methods.
Photonic Pharma LLC is pleased to announce that it was awarded its its third grant from the National Institutes of Health, as a five-year Academic Industrial Partnership grant from the National Cancer Institute to the University of Minnesota, with a $234,000 annual subaward to Photonic Pharma, related to new therapeutic avenues for treatment of cancer through an innovative new approach to developing allosteric kinase inhibitors. The project title is "A transformative drug discovery platform for allosteric kinase inhibitors” (Project Number: R01 CA255513-01). This multi-PI collaboration is led by Principal Investigator, Nicholas M. Levinson (Contact) at the University of Minnesota and David D. Thomas, Principal Investigator at Photonic Pharma. Photonic Pharma holds an Exclusive Patent License Agreement with the University of Minnesota for a patent pending on protein kinase allostery sensor and methods.
2020
July 28, 2020
Photonic Pharma LLC is pleased to announce the extension of our awarded SBIR Phase I grant from the National Institute of Aging at the National Institutes of Health related to new therapeutic avenues for treatment of Alzheimer's disease. The project title is "Fluorescence lifetime platform to discover small-molecule inhibitors of tau and alpha-synuclein oligomerization." (Project number: R43AG063675). The awarded amount is $593,889. This project will be carried out by Photonic Pharma (Principal Investigator: Jennifer Jewell Thomas) in collaboration with the University of Minnesota (Lead Investigator: Jonathan N. Sachs). The grant funding goes through 08/31/2021.
Photonic Pharma LLC is pleased to announce the extension of our awarded SBIR Phase I grant from the National Institute of Aging at the National Institutes of Health related to new therapeutic avenues for treatment of Alzheimer's disease. The project title is "Fluorescence lifetime platform to discover small-molecule inhibitors of tau and alpha-synuclein oligomerization." (Project number: R43AG063675). The awarded amount is $593,889. This project will be carried out by Photonic Pharma (Principal Investigator: Jennifer Jewell Thomas) in collaboration with the University of Minnesota (Lead Investigator: Jonathan N. Sachs). The grant funding goes through 08/31/2021.
August 2020
Photonic Pharma LLC Founder and President, David D. Thomas, was recognized by Sarepta Therapeutics for research at the University of Minnesota that features Photonic Pharma's patented technology for fluorescence-based high-throughput screening in living cells.
Photonic Pharma LLC Founder and President, David D. Thomas, was recognized by Sarepta Therapeutics for research at the University of Minnesota that features Photonic Pharma's patented technology for fluorescence-based high-throughput screening in living cells.
October 6, 2020
Photonic Pharma LLC is pleased to announce that the USPTO has issued the patent on Photonic Pharma's exclusive living cell biosensor assay technology, "High-throughput, high-precision methods for detecting protein structural changes in living cells." More info.
Photonic Pharma LLC is pleased to announce that the USPTO has issued the patent on Photonic Pharma's exclusive living cell biosensor assay technology, "High-throughput, high-precision methods for detecting protein structural changes in living cells." More info.
October 16, 2020
Photonic Pharma LLC is pleased to announce the sixth anniversary of our founding as we begin our seventh year of business. Photonic sends thanks to all those who made this possible.
Photonic Pharma LLC is pleased to announce the sixth anniversary of our founding as we begin our seventh year of business. Photonic sends thanks to all those who made this possible.
News Archive
2014
October 16, 2014
Photonic Pharma LLC is founded and files Articles of Organization with the State of Minnesota.
Photonic Pharma LLC is founded and files Articles of Organization with the State of Minnesota.
2015
December 17, 2015
Photonic Pharma LLC is pleased to announce that it has signed an Exclusive Patent License Agreement with the University of Minnesota. This license includes all commercial rights to one issued patent and two published-but-pending applications related to fluorescence methods in high-throughput screening for drug discovery.
Patent Information
Photonic Pharma LLC is pleased to announce that it has signed an Exclusive Patent License Agreement with the University of Minnesota. This license includes all commercial rights to one issued patent and two published-but-pending applications related to fluorescence methods in high-throughput screening for drug discovery.
Patent Information
December 22, 2015
Photonic Pharma LLC is pleased to announce that it began a multi-year collaboration and license agreement with Bristol-Myers Squibb (NYSE: BMY) effective December 22, 2015.
Photonic Pharma LLC is pleased to announce that it began a multi-year collaboration and license agreement with Bristol-Myers Squibb (NYSE: BMY) effective December 22, 2015.
2016
|
June 7, 2016
Photonic Pharma LLC is honored by its selection as a semifinalist in the 2016 MN Cup startup competition announced on June 7, 2016. MN Cup is the nation's largest statewide new venture competition. Photonic Pharma is one of ten semifinalists competing in the Life Science/Health IT division, and will go on to compete for a share of the record $402,000 in total prize money. Semifinalists also receive mentoring, training, and support to help advance their entrepreneurial ideas. |
|
December 31, 2016
Photonic Pharma LLC is honored to have an image of our proprietary drug discovery technology, featuring fluorescent biosensors in living cells, on the cover of the 2016 Annual Report for the Office for Technology and Commercialization at the University of Minnesota.
Photonic Pharma LLC is honored to have an image of our proprietary drug discovery technology, featuring fluorescent biosensors in living cells, on the cover of the 2016 Annual Report for the Office for Technology and Commercialization at the University of Minnesota.
2017
March 15, 2017
Photonic Pharma LLC is honored by its selection as a shortlisted company being considered for one of the forty presentation slots for the University Startups Conference & Demo Day 2017 by the National Council of Entrepreneurial Tech Transfer (NCET2). Finalists will participate in the event in Washington, D.C. on April 18-20, 2017.
Photonic Pharma LLC is honored by its selection as a shortlisted company being considered for one of the forty presentation slots for the University Startups Conference & Demo Day 2017 by the National Council of Entrepreneurial Tech Transfer (NCET2). Finalists will participate in the event in Washington, D.C. on April 18-20, 2017.
March 21 2017
Photonic Pharma LLC is honored by its selection as one of the 40 "Best University Startups 2017", and will present at the University Startups Conference and Demo Day on April 18-19, 2017 in Washington, D.C.
David D. Thomas, PhD, the President and Co-Founder of Photonic Pharma reports, "I am thrilled that our company has been selected as one of the forty Best University Startups in the USA, by the National Council of Entrepreneurial Tech Transfer (NCET2). Photonic's proprietary technology platform is based on patented research from my lab at the University of Minnesota, resulting in breakthroughs in biomolecular engineering and instrumentation that produce a 30-fold improvement in precision during the early phase of drug discovery. This greatly improves the odds of success in developing promising compounds into successful drugs, as demonstrated by Photonic's recent successful collaboration with a major pharmaceutical company."
Photonic Pharma LLC is honored by its selection as one of the 40 "Best University Startups 2017", and will present at the University Startups Conference and Demo Day on April 18-19, 2017 in Washington, D.C.
David D. Thomas, PhD, the President and Co-Founder of Photonic Pharma reports, "I am thrilled that our company has been selected as one of the forty Best University Startups in the USA, by the National Council of Entrepreneurial Tech Transfer (NCET2). Photonic's proprietary technology platform is based on patented research from my lab at the University of Minnesota, resulting in breakthroughs in biomolecular engineering and instrumentation that produce a 30-fold improvement in precision during the early phase of drug discovery. This greatly improves the odds of success in developing promising compounds into successful drugs, as demonstrated by Photonic's recent successful collaboration with a major pharmaceutical company."
March 28 2017
Photonic Pharma LLC is pleased to report that its two scientific co-founders, David D. Thomas, PhD, and Razvan L. Cornea, PhD, were recognized at the Inventor Recognition Event held by the Offices of the Vice President for Research and Technology Commercialization at the University of Minnesota. The event was "Recognizing the accomplishments of outstanding faculty and staff from the university research community whose work has recently been patented or licensed."
Photonic Pharma LLC is pleased to report that its two scientific co-founders, David D. Thomas, PhD, and Razvan L. Cornea, PhD, were recognized at the Inventor Recognition Event held by the Offices of the Vice President for Research and Technology Commercialization at the University of Minnesota. The event was "Recognizing the accomplishments of outstanding faculty and staff from the university research community whose work has recently been patented or licensed."
April 18, 2017
Photonic Pharma LLC is honored to be one of the 40 "Best University Startups 2017" presenting at the University Startups Conference and Demo Day in Washington, D.C
About Demo Day: The 40 winning startups were chosen from a group of 200 submitted companies launched by universities across the U.S. The University Startups Conference and Demo Day brings together a diverse audience of over three hundred people, including University Startup Officers, university startups, entrepreneurs, Fortune 1000/Global 1000 corporations, VCs, angel investors, policy leaders, and federal government agencies. The event provides a venue to form and maintain robust transaction networks among the participants with the aim to align university IP and startups with investor and corporate needs.
Photonic Pharma LLC is honored to be one of the 40 "Best University Startups 2017" presenting at the University Startups Conference and Demo Day in Washington, D.C
About Demo Day: The 40 winning startups were chosen from a group of 200 submitted companies launched by universities across the U.S. The University Startups Conference and Demo Day brings together a diverse audience of over three hundred people, including University Startup Officers, university startups, entrepreneurs, Fortune 1000/Global 1000 corporations, VCs, angel investors, policy leaders, and federal government agencies. The event provides a venue to form and maintain robust transaction networks among the participants with the aim to align university IP and startups with investor and corporate needs.
April 19, 2017
Photonic Pharma LLC is honored to be selected as a finalist in the Walleye Tank Life Science venture pitch competition at the University of Minnesota.
Photonic Pharma LLC is honored to be selected as a finalist in the Walleye Tank Life Science venture pitch competition at the University of Minnesota.
April 28, 2017
Photonic Pharma LLC is honored to present at the Walleye Tank Pitch Competition, Fishing Opener Edition, on Friday April 28, 2-5PM, at Mondale Hall, University of Minnesota.
Photonic Pharma LLC is honored to present at the Walleye Tank Pitch Competition, Fishing Opener Edition, on Friday April 28, 2-5PM, at Mondale Hall, University of Minnesota.
May 30, 2017
Photonic Pharma LLC is honored by its selection as a semifinalist in the 2017 MN Cup startup competition. This is the second year that Photonic has earned this recognition. MN Cup is the nation's largest statewide new venture competition. Photonic Pharma is one of ten semifinalists competing in the Life Science/Health IT division, and will go on to compete for a share of the record $450,000 in total prize money. Semi finalists also receive mentoring, training, and support to help advance their entrepreneurial ideas.
Photonic Pharma LLC is honored by its selection as a semifinalist in the 2017 MN Cup startup competition. This is the second year that Photonic has earned this recognition. MN Cup is the nation's largest statewide new venture competition. Photonic Pharma is one of ten semifinalists competing in the Life Science/Health IT division, and will go on to compete for a share of the record $450,000 in total prize money. Semi finalists also receive mentoring, training, and support to help advance their entrepreneurial ideas.
September 27, 2017
Photonic Pharma LLC is honored by its selection as a finalist in the 2017 Tekne Awards by the Minnesota High Tech Association (MHTA). Photonic Pharma is one of 3 finalists for the Healthcare Award, which “Honors innovative development or deployment of medical devices, diagnostics or equipment, data management, communication systems integration, disease treatment, or pharmaceuticals that measurably improve patient care delivery, reduce recovery times or improve patient health.”
Photonic Pharma LLC is honored by its selection as a finalist in the 2017 Tekne Awards by the Minnesota High Tech Association (MHTA). Photonic Pharma is one of 3 finalists for the Healthcare Award, which “Honors innovative development or deployment of medical devices, diagnostics or equipment, data management, communication systems integration, disease treatment, or pharmaceuticals that measurably improve patient care delivery, reduce recovery times or improve patient health.”
November 15, 2017
Photonic Pharma LLC was honored as a finalist at the 2017 Tekne Awards annual gala celebration by the Minnesota High Tech Association (MHTA). Photonic’s application was selected as a finalist in the Healthcare category “from among the best and brightest of Minnesota’s diverse tech-based companies, innovations and individuals!” MHTA’s event “shines a spotlight on Minnesota’s science and technology community by honoring innovation across numerous industries, drawing our state’s most influential business, educational and government leaders together to celebrate Minnesota’s science and technology based economy.”
Photonic Pharma LLC was honored as a finalist at the 2017 Tekne Awards annual gala celebration by the Minnesota High Tech Association (MHTA). Photonic’s application was selected as a finalist in the Healthcare category “from among the best and brightest of Minnesota’s diverse tech-based companies, innovations and individuals!” MHTA’s event “shines a spotlight on Minnesota’s science and technology community by honoring innovation across numerous industries, drawing our state’s most influential business, educational and government leaders together to celebrate Minnesota’s science and technology based economy.”
2018
January 2, 2018
Photonic Pharma LLC is pleased to announce that it has signed an expansion and 2-year extension of the research term of its collaboration and license agreement with Bristol-Myers Squibb (NYSE: BMY), effective January 2, 2018.
Photonic Pharma LLC is pleased to announce that it has signed an expansion and 2-year extension of the research term of its collaboration and license agreement with Bristol-Myers Squibb (NYSE: BMY), effective January 2, 2018.
September 28, 2018
Photonic Pharma LLC is honored by its selection as a finalist in the 2018 Tekne Awards by the Minnesota High Tech Association (MHTA). Photonic Pharma is one of three finalists with 3M and StemoniX in the Biotechnology/Pharmaceuticals category, which "celebrates innovation and pioneering efforts in biotechnology or pharmaceuticals to provide game-changing advancement in the healthcare field. Examples include gene therapies, precision medicine, drug discovery and delivery."
Photonic Pharma LLC is honored by its selection as a finalist in the 2018 Tekne Awards by the Minnesota High Tech Association (MHTA). Photonic Pharma is one of three finalists with 3M and StemoniX in the Biotechnology/Pharmaceuticals category, which "celebrates innovation and pioneering efforts in biotechnology or pharmaceuticals to provide game-changing advancement in the healthcare field. Examples include gene therapies, precision medicine, drug discovery and delivery."
2019
September 15, 2019
Photonic Pharma LLC is pleased to announce that it was awarded an SBIR Phase I grant from the National Institute on Aging at the National Institutes of Health related to new therapeutic avenues for treatment of Alzheimer's disease. The project title is "Fluorescence lifetime platform to discover small-molecule inhibitors of tau and alpha-synuclein oligomerization." (Project number: R43AG063675) The awarded amount is $593,889. This project will be carried out by Photonic Pharma (Principal Investigator: Jennifer Jewell Thomas) in collaboration with the University of Minnesota (Lead Investigator: Jonathan N. Sachs).
Photonic Pharma LLC is pleased to announce that it was awarded an SBIR Phase I grant from the National Institute on Aging at the National Institutes of Health related to new therapeutic avenues for treatment of Alzheimer's disease. The project title is "Fluorescence lifetime platform to discover small-molecule inhibitors of tau and alpha-synuclein oligomerization." (Project number: R43AG063675) The awarded amount is $593,889. This project will be carried out by Photonic Pharma (Principal Investigator: Jennifer Jewell Thomas) in collaboration with the University of Minnesota (Lead Investigator: Jonathan N. Sachs).
September 16, 2019
Photonic Pharma LLC is pleased to announce that Bristol-Myers Squibb (NYSE: BMY), has signed a 1-year extension of the research term of a collaboration and license agreement with Photonic Pharma through January 2, 2021.
Photonic Pharma LLC is pleased to announce that Bristol-Myers Squibb (NYSE: BMY), has signed a 1-year extension of the research term of a collaboration and license agreement with Photonic Pharma through January 2, 2021.
October 16, 2019
Photonic Pharma LLC is pleased to announce the fifth anniversary of our founding as we begin our sixth year of business. Photonic sends thanks to all those who made this possible.
Photonic Pharma LLC is pleased to announce the fifth anniversary of our founding as we begin our sixth year of business. Photonic sends thanks to all those who made this possible.